Eli Lilly expands Jaypirca into first-line CLL and SLL treatment, adding an oncology development to its healthcare presence within the S&P 500.

Eli Lilly (LLY) stock is priced at 38.7 times earnings, compared with 21.5 for the S&P 500. Investors evaluating that ...

Moderna ( MRNA) rose roughly 5% and Eli Lilly ( LLY) added nearly 3% to rank among the day’s best-performing stocks in the ...

Eli Lilly (LLY) stock offers diversification vs. AI-heavy portfolios, trading ~24x FY2027 EPS. Read here for a detailed ...

Eli Lilly's bulls are pointing at a 47% revenue surge and a pipeline loaded with blockbuster candidates, but there are a few uncomfortable details quietly buried in the earnings report that change how ...

You may own Eli Lilly (LLY), a drugmaker worth about $1.05 trillion, beside funds that already track the S&P 500. A single ...

When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk.

Citigroup sees a path to 35% gains from here, but Eli Lilly's pricing headwinds, a slow oral GLP-1 launch, and a rival in ...

Top and bottom line beats, with broad drug sales momentum, along with beefy gross margins, made Eli Lilly to raise FY 2026 ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly and Co. stock closed at USD 1,191.40 on the NYSE on September 24, 2026, gaining 3.51 percent. The move outpaced the ...